HMG-CoA还原酶抑制剂可改善急性缺血性卒中的预后。
HMG-CoA reductase inhibitors improve acute ischemic stroke outcome.
作者信息
Moonis Majaz, Kane Kevin, Schwiderski Ute, Sandage Bobby W, Fisher Marc
机构信息
Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA.
出版信息
Stroke. 2005 Jun;36(6):1298-300. doi: 10.1161/01.STR.0000165920.67784.58. Epub 2005 May 5.
BACKGROUND AND PURPOSE
Statins reduce the risk of stroke recurrence, but the benefits of statins in improving outcome of acute stroke patients have not been well explored.
METHODS
We assessed potential effects of statins initiated before or within 4 weeks of stroke on 90-day outcome. Favorable outcomes were National Institutes of Health Stroke Scale (NIHSS) score < or =2 at 12 weeks and modified Rankin Scale (mRS) < or =2.
RESULTS
Before stroke, 129 patients were receiving statins, 123 initiated statins within 4 weeks, and 600 patients were not on statins. Multivariate logistic regression analysis demonstrated that poststroke statins were associated with a significant probability of a favorable outcome at 12 weeks [NIHSS (P=0.002; OR, 1.92; CI, 1.27 to 2.91) and mRS (P=0.033; OR, 1.57; CI, 1.04 to 2.38)], whereas prestroke statins demonstrated a trend toward significance.
CONCLUSIONS
These preliminary results suggest that statin use may improve outcome of acute ischemic stroke.
背景与目的
他汀类药物可降低卒中复发风险，但他汀类药物对改善急性卒中患者预后的益处尚未得到充分研究。
方法
我们评估了在卒中发生前或卒中后4周内开始使用他汀类药物对90天预后的潜在影响。良好预后定义为12周时美国国立卫生研究院卒中量表（NIHSS）评分≤2分以及改良Rankin量表（mRS）评分≤2分。
结果
卒中前，129例患者正在服用他汀类药物，123例在4周内开始使用他汀类药物，600例患者未服用他汀类药物。多因素逻辑回归分析表明，卒中后使用他汀类药物与12周时获得良好预后的显著概率相关[NIHSS（P=0.002；比值比[OR]，1.92；可信区间[CI]，1.27至2.91）和mRS（P=0.033；OR，1.57；CI，1.04至2.38）]，而卒中前使用他汀类药物显示出显著趋势。
结论
这些初步结果表明，使用他汀类药物可能改善急性缺血性卒中的预后。
Zotero 插件